Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient

Emmaus Life Sciences, Inc.

2022-Q3 EPS reported -$0.22 vs consensus $0.01 ▼ miss (-2256.9%)

Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.
Q3 net loss $0.4M ($0.01/shr) vs $3.2M loss in Q3 2021; operating loss $0.7M vs $31k.
Cash and equivalents $1.2M vs $2.3M at Dec 31; working capital insufficient for next 12 months without restructuring.
First Endari sales in UAE (approved May 2022) and early access in GCC countries boosted Q3 revenue.
Company discussing restructuring or refinancing of indebtedness and other current liabilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emmaus Life Sciences, Inc. reported nine months ended September 30, 2022 results: revenue $12.5 million, net income a net loss of $10.8 million, EPS $0.22 per share.

Period: nine months ended September 30, 2022
Revenue: $12.5 million
Net income: a net loss of $10.8 million
EPS: $0.22 per share
Result: reported results

Exact text from the filing

this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order purchases in 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emmaus Life Sciences, Inc. reported three months ended September 30, 2022 results: revenue $4.9 million, net income a net loss of $0.4 million, EPS $0.01 per share.

Period: three months ended September 30, 2022
Revenue: $4.9 million
Net income: a net loss of $0.4 million
EPS: $0.01 per share
Result: reported results

Exact text from the filing

any transactions in this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-072481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.